AstraZeneca has had a setback in its late-stage oncology pipeline, after AKT inhibitor ceralasertib, given in combination with cancer immunotherapy Imfinzi, failed to extend survival in a lung cancer ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Colleen Hagerty Colleen Hagerty is a writer focused on emergency preparedness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback